Since its creation in 1999, IPSOGEN designs, manufactures and markets molecular assays with proven expertise in identifying and translating key discoveries into essential tests intended to support personalized approach to cancer treatment.

The company has developed an integrated approach with R&D capabilities to develop and clinically validate unique biomarkers in-licensed from public institutions.

With more than 80 product references used routinely in 5 continents for the diagnosis, prognosis and monitoring of thousands of patients with leukemia, including its least common forms, IPSOGEN is currently the world leader in blood cancer molecular diagnostics.